English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b

MPS-Authors

Brettschneider,  J.
Max Planck Institute of Psychiatry, Max Planck Society;

Ecker,  D
Max Planck Institute of Psychiatry, Max Planck Society;

Bitsch,  A
Max Planck Institute of Psychiatry, Max Planck Society;

Bahner,  D
Max Planck Institute of Psychiatry, Max Planck Society;

Bogumil,  T
Max Planck Institute of Psychiatry, Max Planck Society;

Dressel,  A
Max Planck Institute of Psychiatry, Max Planck Society;

Elitok,  E
Max Planck Institute of Psychiatry, Max Planck Society;

Kitze,  B
Max Planck Institute of Psychiatry, Max Planck Society;

Poser,  S
Max Planck Institute of Psychiatry, Max Planck Society;

Weber,  F
Max Planck Institute of Psychiatry, Max Planck Society;

Tumani,  H.
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Brettschneider, J., Ecker, D., Bitsch, A., Bahner, D., Bogumil, T., Dressel, A., et al. (2002). The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. Journal of Neuroimmunology, 133(1-2), 193-197.


Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-A003-F
Abstract
The soluble form of the CD14 molecule (sCD14), a macrophage activity marker, was measured in the plasma of 17 patients with primary progressive multiple sclerosis (PPMS) and 20 patients with relapsing remitting MS (RRMS). In patients with PPMS, sCD14 levels were determined before and after treatment with interferon beta (IFNB). In both PPMS and in RRMS, sCD14 levels were significantly elevated compared to healthy controls. In patients with PPMS, sCD14 levels increased significantly during the first 3 months of IFNB therapy, then slightly decreased, but still remained elevated compared with levels before therapy. Therefore, the elevated sCD14 levels may be a marker in evaluating biological response to IFNB therapy. (C) 2002 Elsevier Science B.V. All rights reserved